nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy
|
Yamamoto, Noboru |
|
2018 |
82 |
4 |
p. 685-694 |
artikel |
2 |
A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer
|
Greil, Richard |
|
2018 |
82 |
4 |
p. 695-706 |
artikel |
3 |
A phase I/II study of GLIF combination chemotherapy for taxane/platinum-refractory/resistant endometrial cancer (GOGO-EM2)
|
Tanaka, Yusuke |
|
2018 |
82 |
4 |
p. 585-592 |
artikel |
4 |
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors
|
Liu, Stephen V. |
|
2018 |
82 |
4 |
p. 723-732 |
artikel |
5 |
Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients
|
Akiyama, Kana |
|
2018 |
82 |
4 |
p. 717-721 |
artikel |
6 |
Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer
|
Yamazaki, Haruhiko |
|
2018 |
82 |
4 |
p. 649-654 |
artikel |
7 |
Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1
|
Jain, Mukul R. |
|
2018 |
82 |
4 |
p. 635-647 |
artikel |
8 |
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)
|
Moehler, Markus |
|
2018 |
82 |
4 |
p. 733-739 |
artikel |
9 |
Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand–foot skin reactions in sorafenib-treated patients
|
Saito, Kosuke |
|
2018 |
82 |
4 |
p. 677-684 |
artikel |
10 |
Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy
|
Shibuya, Hitoshi |
|
2018 |
82 |
4 |
p. 661-668 |
artikel |
11 |
Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial
|
Zhang, Wen |
|
2018 |
82 |
4 |
p. 655-660 |
artikel |
12 |
Pharmacodynamic modelling of resistance to epidermal growth factor receptor inhibition in brain metastasis mouse models
|
Martin, Emma C. |
|
2018 |
82 |
4 |
p. 669-675 |
artikel |
13 |
Phase II trial of capecitabine plus oxaliplatin (CAPOX) as perioperative therapy for locally advanced rectal cancer
|
Nishimura, Junichi |
|
2018 |
82 |
4 |
p. 707-716 |
artikel |
14 |
Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer
|
Huang, Weiwei |
|
2018 |
82 |
4 |
p. 607-613 |
artikel |
15 |
Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation
|
Ni, Feng |
|
2018 |
82 |
4 |
p. 593-605 |
artikel |
16 |
Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials
|
Li, Jing |
|
2018 |
82 |
4 |
p. 571-583 |
artikel |
17 |
The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer
|
Yamaguchi, Kyoko |
|
2018 |
82 |
4 |
p. 625-633 |
artikel |
18 |
Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects
|
Zhang, Hong |
|
2018 |
82 |
4 |
p. 615-623 |
artikel |